1 citations
,
June 2024 in “Journal of Clinical Oncology” Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.
15 citations
,
November 2022 in “Cell Death and Disease” CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.
May 2025 in “Journal of Inflammation Research” A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.
April 2019 in “Journal of Investigative Dermatology” Y27632 increases cell growth through EGFR signaling, not ROCK1/2.
Baricitinib shows promise for treating alopecia areata with mild side effects.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
January 2026 in “International Journal of Molecular Sciences” Hedgehog pathway inhibitors could be effective in treating melanoma.
2 citations
,
January 2022 in “JAAD Case Reports” The rash resolved after stopping ponatinib.
1 citations
,
October 2023 in “Life science alliance” Pantethine may boost the immune system's ability to fight sarcoma.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
1 citations
,
April 2025 in “Experimental Dermatology” Topical ruxolitinib may help some skin conditions but needs more research for alopecia areata.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
2 citations
,
August 2021 in “Journal of pharmaceutical research international” Fenugreek seed extract in a nanoparticle gel could be a promising new treatment for hair loss.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
August 2013 in “Nature Reviews Drug Discovery” New treatments for cancer and skin disorders show promise in disrupting harmful cell interactions and promoting hair growth.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
8 citations
,
June 2004 in “Journal of Investigative Dermatology” Certain peptides can prevent hair loss in young rats caused by a cancer drug.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” Gefitinib can cause hair loss without scarring.
46 citations
,
July 2010 in “Advances in Therapy” SPET-085 effectively inhibits an enzyme linked to prostate issues, similar to finasteride.
Cetirizine-loaded gel may effectively promote hair growth in alopecia.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
16 citations
,
August 2023 in “JAAD Case Reports” JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.